ライフサイエンスコーパス: treatment duration

1 20, or 40 weeks (15 rats/treatment; 45 rats/treatment duration).

2 of high use of novel treatments and extended treatment duration.

3 osbuvir and ledipasvir would allow a shorter treatment duration.

4 (HIV-1) depends on both viral load (VL) and treatment duration.

5 lerability profile of SOF and by the shorter treatment duration.

6 on location, gender, age, treatment type, or treatment duration.

7 virological response (SVR) rates and shorten treatment duration.

8 evaluate the possibility of further reducing treatment duration.

9 urce use was measured during the combination treatment duration.

10 12 months after randomization, regardless of treatment duration.

11 ere not influenced by combination therapy or treatment duration.

12 n phase patients demonstrated greater median treatment duration.

13 comes appear to be no worse with the shorter treatment duration.

14 om increased cumulative dose rather than the treatment duration.

15 ensitive to BSC survival rate, and sorafenib treatment duration.

16 QD achieved SVR, irrespective of PegIFN/RBV treatment duration.

17 or no clinical resistance, and the shortest treatment duration.

18 NA at RGT timepoints benefited from extended treatment duration.

19 eductions in CRP and SAA, continued over the treatment duration.

20 (cancer) to prevent late relapse and shorten treatment duration.

21 urvival advantage that improved with greater treatment duration.

22 the use of specific chemotherapy regimens or treatment duration.

23 ool can support clinical decision making for treatment duration.

24 chmarks during therapy can be used to tailor treatment duration.

25 relapse occurred more swiftly regardless of treatment duration.

26 61.8% and 59.5%, respectively) regardless of treatment duration.

27 e the relationship between applied power and treatment duration.

28 y in those with higher baseline HR or longer treatment duration.

29 and are testing the effect of more prolonged treatment duration.

30 improved but only with high doses and longer treatment duration.

31 ll group of individuals because of the short treatment duration.

32 no significant between-group differences in treatment duration.

33 ampicin (35 mg/kg) will significantly reduce treatment duration.

34 rapies which have the potential to reduce TB treatment duration.

35 lation is critical to predicting clinical TB treatment duration.

36 bility of donor organ availability may limit treatment duration.

37 s collected for all patients irrespective of treatment duration.

38 lso inhibited HCMV, an effect augmented with treatment duration.

39 e documented in all patients irrespective of treatment duration.

40 ent characteristics were not associated with treatment duration.

41 as failed, and the feasibility of shortening treatment duration.

42 al trials to compare outcomes after specific treatment durations.

43 rapy and can identify candidates for shorter treatment durations.

44 ologic response among patients receiving two treatment durations.

45 ed to assess efficacy and safety over longer treatment durations.

46 e higher cytotoxicity associated with longer treatment durations.

47 = 317) with a median follow-up of 15 months (treatment duration, 0.03-31.15 months) are reported.

48 esults At a median follow-up of 14.1 months (treatment duration, 0.1 to 21.7 months), major and compl

49 usions of tissue plasminogen activator (mean treatment duration, 11 days).

50 s 15.9 weeks (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (ha

51 At EOP (mean treatment duration, 17 days), clinical success was 98.6%

52 The effect of a short treatment duration (2 weeks) with nilvadipine on regiona

53 weeks of peginterferon and ribavirin (total treatment duration, 28-48 wk).

54 stratified according to country and intended treatment duration (3, 6, or 12 months).

55 d in the intention-to-treat analyses (median treatment duration, 351 days).

56 an 1 month to 14 years received rFIX (median treatment duration, 37 months; range, 4-64 months).

57 , randomized, noninferiority clinical trial (treatment duration, 4 months; follow-ups, 6 months and 1

58 ted with a poor risk benefit profile, a long treatment duration (48 weeks) and inadequate success rat

59 With minimum follow-up of 6 months (median treatment duration, 8 months; range, < 1 to 15 months),

60 y was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR],

61 idual dosing regimens (240-1920 mg/d; median treatment duration, 90 days).

62 men of approximately the same total (weekly) treatment duration, a daily/short-time regimen results i

63 study was to identify the minimum effective treatment duration across multiple genotypes.

64 Antimicrobial use, treatment duration, Acute Physiology and Chronic Health

65 from clinical trials show that drug dose and treatment duration affect both the risk of developing th

66 ly affected by vasoconstrictor dose or type, treatment duration, age, baseline serum creatinine, bili

67 ration therapy was achieved through extended treatment duration and addition of ribavirin.

68 reas not covered by the performance measures-treatment duration and antimicrobial selection after add

69 Drug regimens that shorten treatment duration and are efficacious against drug-resi

70 ex CNS infections and may have relevance for treatment duration and assessment of persistent or recur

71 l recently, data on the relationship between treatment duration and associated cardiovascular risk we

72 as good indicators for the consideration of treatment duration and cessation for chronic hepatitis B

73 There was no interaction between treatment duration and chemotherapy regimen, ER/PgR, or

74 fear of side effects and concerns regarding treatment duration and cost.

75 -acting antivirals, which also offer reduced treatment duration and decreased toxicities, mean that p

76 We use this model to predict the effects of treatment duration and different doses of ALV plus RBV o

77 The immediate effect increased with treatment duration and drug concentration.

78 tently infected cells could therefore reduce treatment duration and facilitate immune reconstitution.

79 ons, and interferon-free regimens with short treatment duration and fewer side effects are the future

80 virus (HCV) have evolved to provide shorter treatment duration and higher rates of sustained virolog

81 ion of the regimen could potentially prolong treatment duration and improve patients' outcomes, altho

82 enotype 1 HCV in HIV-infected men halved the treatment duration and increased the SVR rate.

83 itical to improving TB-therapy is shortening treatment duration and increasing therapeutic efficacy.

84 interferon-based treatment, but with shorter treatment duration and more favourable safety outcomes.

85 We calculated an observed/expected ratio of treatment duration and of completed chemotherapy cycles

86 Depending on the treatment duration and onset time relative to the stage

87 The current status quo of the lengthy treatment duration and poor treatment outcomes associate

88 The lengthy tuberculosis treatment duration and poor treatment outcomes associate

89 e treated with rituximab had shorter overall treatment duration and reduced 1-yr relapses than histor

90 Two patients reached the maximum 2-year treatment duration and remain in remission.

91 The association of treatment duration and survival was unstable when analyz

92 tion, and to assess the relationship between treatment duration and survival.

93 valid assessment of the association between treatment duration and survival.

94 quiring further research include the optimal treatment duration and the establishment of the optimal

95 cardiovascular magnetic resonance to inform treatment duration and the need to compare steroid-spari

96 tive at curing chronic infections, judged by treatment duration and therapeutic dose.

97 sion is, however, strictly dependent on both treatment duration and time after the last administratio

98 ical trials are needed to establish the best treatment duration and to further assess the contributio

99 e; P = .0053) were experienced regardless of treatment duration and were similar to those for HCV-mon

100 ens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained vir

101 Long treatment durations and severe side effects have limited

102 Clinical data were collected on natalizumab treatment, duration and management of the washout period

103 treatment characteristics (e.g., antibiotic, treatment duration) and outcome measures (e.g., mortalit

104 However, optimal dosage, treatment duration, and bioactivity must be studied to a

105 For each DAA, molecular structures, doses, treatment duration, and components of retrosynthesis wer

106 es are needed to improve cure rates, shorten treatment duration, and improve tolerability.

107 timulation parameters (frequency, intensity, treatment duration, and pulse width).

108 ge at which to initiate therapy, the optimum treatment duration, and the subpopulations for which the

109 o assess pathogen/patient factors related to treatment duration, and to assess the relationship betwe

110 ficant correlation was observed between age, treatment duration, and total dose and the development o

111 in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to

112 With increasing age and treatment duration, antiepileptic drug withdrawal may be

113 and detailed information on drug dosage and treatment duration are needed.

114 -containing trials of mericitabine of longer treatment duration are ongoing.

115 codynamic models more predictive of curative treatment durations are set forth.

116 hodological issues, such as optimal dose and treatment duration, are needed.

117 ients were subdivided by the 12- and 24-week treatment duration arms, HCV genotype, fibrosis stage, a

118 eceive a different and potentially incorrect treatment duration based solely on HCV RNA test method u

119 pes were tested using linear regression with treatment duration, baseline body weight, and medication

120 e, baseline visual acuity (VA), lesion size, treatment duration before tearing, and duration of follo

121 artan (150 mg daily) and placebo with target treatment duration between 18 and 24 months.

122 Fisher exact tests compared planned adjuvant treatment duration between groups.

123 by resistance, and that are more confined in treatment duration but are more durable.

124 eatment for >10 years; patients with similar treatment duration but initiation of suppressive therapy

125 ghting bleeding risk before the selection of treatment duration, but no standardised tool exists for

126 Conversely, antipsychotic treatment duration correlated significantly with higher

127 that the study type, adjustment for age/sex, treatment duration, cumulative dose, agents used in a co

128 ents in remission decreases as a function of treatment duration, degree of remission, or both.

129 Treatment with sorafenib resulted in a treatment duration-dependent significantly decreased upt

130 coustic pressure, microbubble concentration, treatment duration, DNA dosage, and number of treatments

131 tors, including the heterogeneity of asthma, treatment duration, dose, and differing outcome measures

132 reviews current attempts at shortening this treatment duration, emphasizing the likelihood of inconc

133 or patients who are still viremic at week 4, treatment durations even longer than 24 weeks are advise

134 The optimal antimicrobial regimen and treatment duration for acute uncomplicated pyelonephriti

135 cure rates and the possibility of shortened treatment duration for diverse patient populations.

136 xed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3

137 ese findings suggest leads about the optimal treatment duration for specific subtypes of psychopathol

138 nd tested the optimal combination, dose, and treatment duration for the prevention of T1D in NOD mice

139 c barrier to resistance, and provide shorter treatment durations for diverse patient populations.

140 rience has shown improved response rates and treatment durations for many patients with genotype 1 HC

141 PF and MTT were correlated with CCl(4) treatment duration from 0 through 16 weeks (r = -0.483,

142 FWR and DV were correlated with CCl(4) treatment duration from 0 through 8 weeks (r = 0.658, P

143 of the use of ribavirin or extension of the treatment duration from 12 to 18 weeks; SVR12 rates rang

144 Conclusion: Extending the treatment duration from 48 weeks to 72 weeks in genotype

145 n, and cyclophosphamide, which shortened the treatment duration from 49 to 29 days.

146 t still substantial impact: shortening RS TB treatment duration from 6 to 2 mo lowered TB mortality b

147 seline at 96 weeks post-therapy for the long-treatment duration group (P = 0.03) and lower than basel

148 Nonresponse at day 3 was a predictor of treatment duration >14 days, but not of clinical failure

149 ve incidence of optic neuropathy with longer treatment duration (>41 vs. </=41 days; HR, 3.46; 95% CI

150 etrospective assessment of DAPT score-guided treatment duration in a randomized clinical trial.

151 possibly caused by higher doses and extended treatment duration in the individualized group.

152 ysis of all randomised, controlled trials of treatment duration in various cardiovascular disorders.

153 ination as a single formulation in different treatment durations in a broader population.

154 n therapy even when administered for shorter treatment durations in conjunction with definitive local

155 t clinical trials of regimens with different treatment durations in treatment-naive and treatment-exp

156 antially higher response rates, with shorter treatment durations, in the majority of genotype 1 infec

157 Extended treatment duration increased SVR rates (16% for 72 weeks

158 t, total cumulative dose of methylphenidate, treatment duration, IQ, severity of hyperactivity, socio

159 h just 75 mg at the time of the PCI when the treatment duration is <12 h.

160 Eligibility for shortened treatment duration is based on achieving undetectable HC

161 hat most responses are, however, partial and treatment duration is indefinite have stimulated interes

162 The optimum treatment duration is unclear, but because the prothromb

163 the higher activity observed for the longer treatment durations is due to a delayed exhibition of dr

164 ical isolates increased proportionately with treatment duration, it is likely that viral resistance w

165 Further studies are needed to assess longer treatment duration, larger samples, and direct compariso

166 ment in EF for crossover trials, trials with treatment duration </=12 wk in length, studies published

167 e observed over a broad range of clopidogrel treatment durations (<6 months, 6 months to 1 year, 1 to

168 ers treatment initiation, regimen design and treatment duration, management of comorbid conditions, t

169 or more than 20 months, whereas much shorter treatment durations may be possible to achieve cure for

170 ge (mean, 36 microg/kg per day [SD, 21]) and treatment duration (mean, 20 days [SD, 18] for studies g

171 14 microg per kg of body weight [SD, 7]) and treatment duration (mean, 27 weeks [SD, 16]) varied.

172 Shortening of treatment duration might be achievable using an increase

173 ithout cirrhosis are limited; shortening the treatment duration might reduce the burden associated wi

174 had significantly greater disease duration, treatment duration, motor severity and complications, sl

175 to prasugrel or ticagrelor with an intended treatment duration of 12 months.

176 9 were simultaneously initiated with a total treatment duration of 12 weeks.

177 l tolerated by all patients, with an average treatment duration of 16.5 cycles (range, 5 to 33).

178 0.51 +/- 0.25 mg/kg per week, with a median treatment duration of 18 months (interquartile range 3-1

179 e ibuprofen group (2045+/-246 mg) for a mean treatment duration of 20.3+/-16.0 months and a mean foll

180 (375 mg/m(2)) on cycles 2 and 5, for a total treatment duration of 23 weeks.

181 llow-up was until July 31, 2015, with a mean treatment duration of 3.4 years (SD 0.4, range 2.5-4.2).

182 atment) in 3 doses 14 days apart for a total treatment duration of 4 weeks, resulting in a total dose

183 h primary open-angle glaucoma with a minimum treatment duration of 4 weeks.

184 kin pigmentation appeared after a median HCQ treatment duration of 6.1 years (range, 3 months-22 year

185 At a mean treatment duration of 6.4 months, the overall response r

186 dded to standard antipsychotic therapy for a treatment duration of 8 weeks.

187 mean dose intensity (DI) was 95% with median treatment duration of approximately 9 months.

188 Studies of outpatients that had a treatment duration of at least 1 year, assessed the impa

189 o assess the efficacy, safety, and effective treatment duration of grazoprevir (an HCV NS3/4A proteas

190 of the comparative efficacy and appropriate treatment duration of injectables are recommended.

191 ed no glucocorticoid treatment or cumulative treatment duration of less than 1 month versus treatment

192 cipants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall s

193 icial effect was seen in those trials with a treatment duration of more than 36 months (0.71, 0.57-0.

194 east 1000 participants and at least 2 years' treatment duration of more versus less intensive statin

195 assess the safety and efficacy of an 8-week treatment duration of once-daily oral ombitasvir 25 mg,

196 f treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these pati

197 without loss of efficacy, currently reaching treatment durations of 17 (case 1) to 44 months (case 3)

198 160 patients had received placebo for median treatment durations of 7.4 and 8.2 months, respectively.

199 o 90 days after clopidogrel cessation in all treatment durations of clopidogrel investigated after SV

200 New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have

201 as predicted by hospitalization, neuroleptic treatment, duration of illness, enduring impairment, and

202 s, 7-year mean glycated hemoglobin, diabetes treatment, duration of insulin use, hyperlipidemia, hype

203 s of the patients, need and type of surgical treatment, duration of operation, perioperative bleeding

204 diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinu

205 de of drug-related side effects; response to treatment; duration of follow-up, and status at last fol

206 esence of vasculitis, prior immunomodulatory treatments, duration of infliximab treatment, dose recei

207 (applied voltage x frequency x pulse width x treatment duration) of about 4700 Vs, there is a thresho

208 ta in the literature regarding the effect of treatment duration on paclitaxel activity under in vitro

209 els estimated the impact of planned adjuvant treatment duration on RFS.

210 We also compared the effect of treatment and treatment duration on survival in the HCV-infected group

211 ab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v

212 After adjusting for drug exposure and treatment duration, only decreases in neutrophil count r

213 py did not differ significantly according to treatment duration or dosage among ribavirin-containing

214 Reducing treatment duration or improving ease of adherence had sm

215 timalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug conc

216 Longer treatment duration or the use of different regimen may s

217 they could be largely overcome by extending treatment duration or through treatment intensification.

218 O scores declined (up to -5.5% regardless of treatment duration; P < 0.0001).

219 y adverse events (15%) did not increase with treatment duration past 1 year.

220 r infectious diseases, with implications for treatment duration, patient compliance, and more optimal

221 Longer treatment durations produced stronger CSD suppression.

222 ary annual out-of-pocket costs for a typical treatment duration ranged from $6,456 (interquartile ran

223 Study drug treatment duration ranged from 4 months to 3.5 years.

224 The treatment duration ranged from 6 weeks to 3 years.

225 Significant harm is possible with treatment durations ranging from 5-24 hours, which may r

226 y drug, and safety analyses were done by the treatment duration received (12 weeks or 16 weeks).

227 these effects will be sustained with longer treatment durations remains to be determined.

228 blished data are conflicting regarding dose, treatment duration, requirement for combinatorial agents

229 ers to improvements in outcomes include long treatment duration (resulting in poor patient adherence

230 asis need to be established, although longer treatment duration seems to confer better results.

231 covery with older age, Asian origin, shorter treatment duration, shorter-acting testosterone preparat

232 Eligibility for shortened treatment duration should be based on achieving undetect

233 The analyses of treatment duration showed that 1 year after the initiati

234 hout ribavirin and for both 12 and 18 weeks' treatment duration, showed high rates of efficacy in pre

235 ogen characteristics are not associated with treatment duration; survivor bias precludes a valid asse

236 Co-infected patients may require longer treatment duration than monoinfected patients given thei

237 h different mechanisms may allow for shorter treatment durations that are effective across multiple g

238 e easily controlled by changing the AC field treatment duration, thus opening the pathway to combined

239 ed treatment could allow a reduction in mean treatment duration to 25.3 weeks and attain a 78.6% SVR

240 Administration of HR(80)Z allowed 9-week treatment duration to be effective without relapse of in

241 direct-acting antiviral regimens will allow treatment duration to be shortened in recent, predominan

242 liver high rifapentine exposures can shorten treatment duration to less than 6 months.

243 However, shortening the treatment duration to less than 8 weeks could potentiall

244 The median treatment duration to onset of symptoms was 25 months (r

245 e eligible for response-guided shortening of treatment duration to W28 and all of these patients had

246 criteria required for registration, shorten treatment duration, treat drug-resistant infection, and

247 However, despite very short treatment duration UHPH may lead to changes in chemical

248 ral antibiotic switch after >/=5 days (total treatment duration up to 10 days or 14 days for patients

249 ients and study investigators were masked to treatment duration up to week 12 but not to treatment al

250 ex vivo and 50-W increments in vivo), while treatment duration varied from 2 to 20 minutes (in eight

251 Treatment duration varied from less than 6 months to mor

252 The mean treatment duration was 11 weeks (range, 4-16 weeks), and

253 The intended treatment duration was 14 days.Main Outcomes Serum liver

254 Median treatment duration was 16 days (range, 3 to 29 days).

255 Treatment duration was 16 weeks.

256 Median treatment duration was 16.6 months (IQR 10.1-21.1) in th

257 Average treatment duration was 18 months (SD 11.8).

258 Mean treatment duration was 19.4 years (SD 2.2) with an avera

259 Treatment duration was 2.5 years.

260 Median treatment duration was 2.6 years (IQR 2.0-3.4; 136 weeks

261 Median treatment duration was 22 weeks in both arms.

262 The median treatment duration was 22.5 weeks.

263 Total treatment duration was 24 weeks or 48 weeks (simeprevir

264 Treatment duration was 24 weeks or 48 weeks in the simep

265 Treatment duration was 26 weeks.

266 The median treatment duration was 3.5 months.

267 Mean treatment duration was 46 weeks.

268 irenz and lamivudine/zidovudine; the planned treatment duration was 48 weeks.

269 Mean treatment duration was 5.8 months, and median duration o

270 rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6),

271 Mean treatment duration was 6.9 months; mean interval from tr

272 Median treatment duration was 7 months (range, 1 to >/= 29 mont

273 Median treatment duration was 8 weeks (range, 2 to 104 weeks),

274 The median treatment duration was 8.3 months; 46% of patients were

275 Median treatment duration was 9 months.

276 r pharmacological therapies for BPH, and the treatment duration was at least 30 days.

277 Treatment duration was event-driven, and interim analyse

278 However, when treatment duration was extended to 24 h, we observed a d

279 The median treatment duration was four cycles (85 days; range, 14 t

280 Treatment duration was scheduled for 1 year and stopped

281 In treated neonates, NAS treatment duration was shorter (-8.46 days, 95% CI: -14.

282 Treatment duration was variable, ending 48 weeks after t

283 ; 95% CI, 0.76-0.95; P<0.01) 12 months after treatment; duration was not significantly associated wit

284 The median overall survival and treatment duration were 85.8 and 40.1 months, respective

285 Treatment effects after covarying for treatment duration were also found for PCS and several s

286 Power and treatment duration were both associated with coagulation

287 , clinical setting, levosimendan dosage, and treatment duration were extracted.

288 f MDS/AML and patient gender, G-CSF dose, or treatment duration were found (P >.15).

289 The median treatment durations were 19.5 versus 24 weeks (IM862 v p

290 rts indicate a higher activity by prolonging treatment durations, whereas other reports indicate no e

291 n serum, previous immunosuppressant use, and treatment duration, which were estimated using populatio

292 Treatment duration with 10 mg lorcaserin twice daily or

293 The influence of the treatment duration with a 600-mg dose of clopidogrel bef

294 f the patients would be eligible for shorter treatment duration with Abbott RealTime versus 72% with

295 sociation of early treatment termination and treatment duration with all-cause mortality, controlling

296 was undertaken to assess whether shortening treatment duration with hyperfractionated RT would be fe

297 similar in each group despite longer median treatment duration with siltuximab than with placebo (37

298 des were characterized by a relatively short treatment duration, yet the women had a notably high rat